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SYNTAX scoreAbstract Background: Neurohumoral activation of the heart can be monitored by measurements
of systemic levels of natriuretic peptides, such as BNP. Patients with non ST-elevation myocardial
infarction (NSTEMI) with elevated BNP levels had an increased mortality rate when compared
with those with lower levels. The SYNTAX score is a novel anatomical tool characterizing coronary
vasculature and grades the complexity of coronary artery disease.
Patients and methods: The study included 58 patients with NSTEMI ‘‘Group I’’ (72.5%) and 22
patients as a control ‘‘Group II’’ (27.5%) with typical chest pain, and coronary angiography
revealed healthy coronaries. Analysis of blood samples for troponin-I, CKMB, and BNP levels
was performed within 24 h of hospital admission, all patients underwent echocardiographic exam-
ination to exclude systolic dysfunction. Both groups were referred to coronary angiography.
Results: This study included 58 patients with NSTEMI ‘‘Group I’’ (72.5%) and 22 patients as a
control ‘‘Group II’’ (27.5%), the serum level of BNP was signiﬁcantly higher in patients with the
NSTEMI ‘‘group I’’ (37.7 ± 32.06) than the control ‘‘group II’’ (1.82 ± 5.9) p value (0.0001).
The levels of BNP were positively correlated with the LAD involvement in coronary angiography.
There was a positive correlation between the serum level of BNP and number of coronary vessels
involved (r= 0.75) and Degree of SYNTAX score (r= 0.78).
Conclusion: There was a signiﬁcant relationship between the serum level of BNP and number of
coronary arteries involved and complexity of the lesions in NSTEMI as regards SYNTAX score.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Natriuretic peptides, such as brain type [B-type natriuretic
peptide (BNP)] or its N-terminal pro hormone fragment
(NT-pro BNP), are highly sensitive and fairly speciﬁc markers
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robust retrospective data on non ST-elevation acute coronary
syndrome (NSTE-ACS) showing that patients with elevated
BNP or NT-pro BNP levels have a three- to ﬁvefold increased
mortality rate when compared with those with lower levels.1
Natriuretic peptides (NPs) are released from the heart in re-
sponse to pressure and volume overload. B-type natriuretic
peptide (BNP) and N-terminal-pro BNP have become impor-
tant diagnostic tools for assessing patients who present acutely
with dyspnea. The NP level reﬂects a compilation of systolic
and diastolic functions as well as right ventricular and valvular
functions.2 Coronary syndromes without ST- elevation are a
heterogeneous disorder ranging from stable angina (SA) with-
out evidence of myocardial necrosis, to myocardial infarction
(NSTE-ACS). Because of different clinical presentations, cor-
onary syndromes without ST- elevation encompass a wide
range of events and have different prognostic values in relation
to the type of plaque lesions and the diffusion of coronary ath-
erosclerosis.3 The SYNTAX score is a novel anatomical tool
characterizing coronary vasculature. Importantly, the SYN-
TAX score grades the complexity of coronary artery disease
and does not consider lesion treatment.41.1. The aim of the study
The purpose of this study is to evaluate the relation between
serum B-type brain natriuretic peptide level and complexity
and severity of coronary artery disease in non- ST- elevation
myocardial infarction with normal left ventricular systolic
function as regards SYNTAX score.2. Patients and methods
The current study was carried out in TheDepartment of Cardiol-
ogy & The Department of Clinical Pathology, El-Minia Univer-
sity during the period from September 2009 to December 2010.
The study included 58 patients ‘‘Group I’’ with non ST- segment
elevation myocardial infarction (NSTEMI) (72.5%). And 22 pa-
tients as a control ‘‘Group II’’ (27.5%)with typical chest pain, and
coronary angiography revealed healthy coronaries.
2.1. Exclusion criteria
- Clinical signs or symptoms of CHF.
- CVS (cerebrovascular stroke).
- Recent infection or inﬂammatory conditions.
- Malignancy.
- Valvular lesions.
- Renal failure.
- Obesity.
- Current major hepatic disease.
- Surgery or major trauma.
- previous myocardial infarction.
NSTEMI was diagnosed when an elevation of troponin-I
levels (>1.0 ng/mL in any sample during the ﬁrst 9 h post-
admission) and/or a typical CKMB curve occurred, with or
without ST/T changes in the ECG, in the absence of any other
demonstrable cause for the chest pain.53. Echocardiography
All patients underwent echocardiographic examination (GE
Vingmed ultrasound, Horten, Norway, model Vivid 3 Expert)
to evaluate left ventricular systolic function, and to exclude
any dysfunction.6
4. Laboratory assays
Blood sample analysis for BNP was performed within 24 h of
hospital admission. Sixty milliliters of blood was taken from a
peripheral vein and distributed in tubes for BNP detection, and
lipid proﬁle within the ﬁrst 3 days of hospital admission.
Plasma BNP was immediately analyzed on the same EDTA-
anti-coagulated blood sample collected on admission for CK-
MB and troponin-I, using the quantitative immunoﬂuorescence
assay. Plasma troponin-I wasmeasured by immunoﬂuorescence
assay manufactured by Dade–Behring. The analytic sensitivity
of the assay is 0.1 ng/mLand the upper normal limit for the diag-
nosis of AMI was considered to be 1.0 ng/mL.
5. Angiographic analysis
Left cardiac catheterization and coronary angiography were
performed. All coronary angiograms were evaluated according
to the SYNTAX score which is a novel anatomical tool char-
acterizing coronary vasculature. It grades the complexity of
coronary artery disease and does not consider lesion treat-
ment.7 The SYNTAX score is the sum of the points assigned
to each individual lesion identiﬁed in the coronary tree with
>50% diameter narrowing in vessels >1.5 mm diameter.
The coronary tree is divided into 16 segments according to
the AHA classiﬁcation. Each segment is given a score of 1 or
2 based on the presence of disease and this score is then
weighted based on a chart, with values ranging from 3.5 for
the proximal left anterior descending artery (LAD) to 5.0 for
left main, and 0.5 for smaller branches.8 The SYNTAX score
was used in a series of patients undergoing three-vessel PCI.
Low SYNTAX scores are <18, intermediate SYNTAX scores
range from 18 to 27 and high SYNTAX scores are >27. High
scores are associated with increasing cardiac mortality, major
adverse cardiac events, and a speciﬁc, predeﬁned combination
of end points.9
5.1. Statistical analysis
Discrete values were presented as counts and percentages.
Continuous values were expressed as mean ± SD. Signiﬁcance
was determined using the t-test. A probability level of
P < 0.05 was considered signiﬁcant. A student unpaired t-test
was used to analyze differences between patients groups.
Correlations between variables were calculated according
to Spearman–Rho. Univariate logistic regression analysis
was performed between the serum level of BNP and number
of coronary vessels involved and degree of SYNTAX score,
grades of r: 0.00–0.24 (weak or no association), 0.25–0.49 (fair
association), 0.50 to 0.74 (moderate association), 0.75+
(strong association).
Data were analyzed by SPSS software (statistical Package
for the Social science).
Table 1 Demographic characteristics of the studied groups.
Variables Group I (no = 58) Group II (no = 22) P
Age (years) 55.3 ± 11.06 49.8 ± 12.01 0.05
Sex males/females 31/27 3/19 –
Diabetes mellitus 34 (58.6%) 9 (40%) 0.001
Hypertension 48 (82.8%) 16 (72.7%) 0.001
Smoking 27 (46.6%) 2 (9.1%) 0.001
Obesity 26 (44.8%) 6 (27.3%) 0.001
Dyslipidemia 24 (41.4%) 4 (18.2%) 0.001
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The study included 58 patients with NSTEMI ‘‘Group I’’
(72.5%) and 22 individuals as a control ‘‘Group II’’ (27.5%),
31 males and 27 females. The mean age was
55.3 ± 11.06 years. The patients were further sub divided
according to coronary angiographic involvement: 0 vessel
which has no or non signiﬁcant coronary artery lesion (less
than 70% obstruction of the lumen in any coronary artery),
1 vessel, 2 vessel and 3 vessel disease.
The baseline characteristics of the patients in both groups
presented in Table 1. showed that ‘‘Group I’’ had more fre-
quent smoking habits, DM, hypertension, dyslipidemia and
obesity than ‘‘Group II’’. The serum level of BNP was signif-
icantly higher in patients with NSTEMI ‘‘Group I’’
(37.7 ± 32.06) than the control ‘‘Group II’’ (1.82 ± 5.9) p va-
lue (0.0001) (Fig. 1).
The study showed a positive correlation between number of
coronary vessels involved and the degree of SYNTAX score,
low SYNTAX score corresponding to I vessel involvement,
intermediate score is related to 2 vessel involvement and High
score correlated to 3 vessel involvement.(Fig. 2).
The levels of BNP were positively correlated with the LAD
involvement in coronary angiography. (Table 2).37.7
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Figure 1 Comparison of serum BNPThere was a positive correlation between the serum level of
BNP and number of coronary vessels involved. (r= 0.75)
(Table 3).
Table 4: shows a positive correlation between the serum le-
vel of BNP and Degree of SYNTAX score (r= 0.78) (Fig. 3).
7. Discussion
B-type natriuretic peptide (BNP) has been used recently as a
biological marker in patients with coronary artery disease
(CAD) with ST-elevation, as well as without ST-elevation.
BNP is able to predict systolic dysfunction, adding new prog-
nostic information to existing traditional markers. However it
is not known if there is a relation between the quantity of BNP
levels and the severity of coronary artery disease,10 and the cir-
culating BNP levels appear elevated in ACS with diffuse coro-
nary involvement, even in the absence of systolic dysfunction.
Mega et al.11 found that there were no enough data on the util-
ity and importance of BNP as an early diagnostic cardiac bio-
marker and prediction of the outcomes of ACS. Hazinski
et al.12 recommend that there was insufﬁcient evidence to sup-
port the use of myoglobin, (BNP), NT-pro BNP, D-dimer, C-
reactive protein, ischemia-modiﬁed albumin pregnancy-associ-
ated plasma protein A (PAPP-A), and/or interleukin-6 in1.82
Group II
among groups. *p value 60.0001.
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Figure 2 Comparison of serum BNP level and number of coronary vessel involvement. There is statistically signiﬁcant increase with the
progress of the disease. *p 6 0.01, **pP 0.001, ***pP 0.0001, ****pP 0.0001 (As compared with control).
Table 4 correlation between SYNTAX score and BNP in
patients with NSTEMI.
Variable SYNTAX score
r p
Pro BNP(pg/ml) 0.78 0.0001
Table 2 LAD angiographic involvement and serum BNP level in patients with NSTEMI.
LAD involvement No of patients (total = 80) Pro BNP(pg/l) mean ± SD P value
LAD involvement 32 105.6 ± 14.7
Non-LAD involvement 26 40.7 ± 20.5 0.01
Table 3 Correlation between BNP and number of coronary
vessels involvement in patients with NSTEMI.
Variable Angiographic involvement
r
Pro BNP(pg/ml) 0.75 0.0001
266 K.S. Mahmoud et al.isolation as primary tests to evaluate patients with symptoms
suspicious for cardiac ischemia. On the other hand, Talwar
et al.13 did not ﬁnd a difference between the BNP levels in pa-
tients with stable coronary artery disease and healthy controls.
In our study there was a signiﬁcant association between the
serum level of BNP and the presence and extension of coro-
nary artery lesion, this was in agreement with Alprto et al.10
and in contrary to Mega et al.11.Recently exercise-induced elevations of (NT-pro) BNP in
coronary artery disease patients have been reported to result
from exercise-induced ischemia associated with regional wall
abnormalities.13 The increase in BNP levels in case of acute
coronary artery disease may be a result of both transient ven-
tricular dysfunction and the increased ventricular BNP genetic
expression.14,15 In the present study, BNP level was more sig-
niﬁcant in patients with the higher number of involved coro-
nary vessels. These results were in agreement with those of
Ariane16 who found in the setting of acute STEMI that in-
creased BNP values were associated with underlying triple-ves-
sel disease, LAD culprit stenosis, higher Killip classiﬁcation,
cardiogenic shock, grade 3/4 left ventricular diastolic dysfunc-
tion and faced higher inpatient mortality. The pathophysiol-
ogy underlying the release of BNP in acute coronary
syndromes remains incompletely deﬁned but is likely explained
in part by the determinants of wall stress.17 Wall stress in the
ventricle is directly related to the diameter and the transmural
pressure and inversely related to the thickness of the wall.
Therefore, increases in either the diameter or pressure during
remodeling after a transmural infarction, or as a consequence
of prior ischemic damage, may contribute to the increase in
natriuretic peptides observed in patients with acute myocardial
infarction (MI).19 The strong association between BNP and
mortality in patients without myocardial necrosis suggests that
the biomarker likely also reﬂects the extent or severity of the
120.00100.0080.0060.0040.0020.000.00
B naturitic peptide ((pg/ml)
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
Sy
nt
ax
 s
co
re
r= 0.78    p= 0.0001
Figure 3 Positive correlation between serum BNP and SYNTAX score (r= 0.75) in group I.
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ischemia itself may be an important stimulus for BNP synthe-
sis and release.18–22 In the present study, there was a clear rela-
tionship between the plasma levels of BNP and LAD
involvement on coronary angiography. The increased plasma
levels of BNP were more signiﬁcant in patients with LAD
involvement. This result was in agreement with the result of
Sahinarslan et al.22 who found a positive correlation between
BNP and LAD involvement which was related to the left ven-
tricular ejection fraction. This may be explained by the greater
amount of myocardium which gets blood through LAD, thus a
signiﬁcant obstruction of LAD can lead to depression of
LVEF more than the other coronary arteries.23 It represents
a marker of coronary disease severity and is related to the pres-
ence of plaque diffusion and narrowing. For the above men-
tioned reasons BNP should be considered as an indicator of
regional ischemia and as a predictor of adverse events in pa-
tients with chest pain.24,25,138. Conclusion
There was a signiﬁcant relationship between the serum level of
BNP and number of coronary arteries involved and complexity
of the lesions in non ST-elevation myocardial infarction as re-
gards SYNTAX score.References
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